Press Releases

IVI to develop an adaptive Phase 1b/2a schistosomiasis vaccine clinical trial

May 31, 2021 – SEOUL, South Korea – The International Vaccine Institute (IVI) announced today that the Bill & Melinda Gates Foundation awarded a grant to IVI to develop an adaptive trial design protocol for a Phase 1b/2a clinical trial of a schistosomiasis vaccine.   […]

International Vaccine Institute and FII Institute sign MOU to cooperate on scientific research and publication

The agreement is an effort to further scientific research in infectious diseases and make knowledge more accessible through advocacy and joint publications.   May 19, 2021 – SEOUL, South Korea, RIYADH, Saudi Arabia – The International Vaccine Institute (IVI) and the Future Investment Initiative Institute […]

International Vaccine Institute and Institut Pasteur Korea Sign MOU for Research and Development of Infectious Disease Therapeutics and Vaccines

April 1, 2021, GYEONGDO-DO and SEOUL, Korea – The International Vaccine Institute (IVI) and the Institut Pasteur Korea (IPK) signed a memorandum of understanding (MOU) for mutual collaboration in the research and development of therapeutics and vaccines for infectious diseases.   The MOU signing ceremony, […]

IVI signs Memorandum of Understanding with the Nepal Health Research Council

  March 12, 2021 – SEOUL, South Korea – The International Vaccine Institute (IVI) and the Nepal Health Research Council (NHRC) signed a Memorandum of Understanding (MoU) today during a virtual ceremony, laying the foundation for the two organizations to build research and development capacity […]

IVI welcomes Bangladesh’s accession to IVI

March 9, 2021 – SEOUL, South Korea – The International Vaccine Institute (IVI) welcomes the Cabinet of Bangladesh’s decision to ratify the IVI Establishment Agreement on February 22, 2021, completing the full accession process to IVI and becoming its 19th State Party.     Bangladesh is a founding signatory to IVI’s […]

George Bickerstaff re-elected Chairperson of the International Vaccine Institute’s Board of Trustees

February 22, 2021, SEOUL, Korea – The International Vaccine Institute (IVI) announced today that its Board of Trustees (BOT) re-elected Mr. George Bickerstaff as Chairperson of the BOT. His second three-year term will begin this May.   Mr. Bickerstaff has served on the IVI Board […]

GI-Cell, IVI sign MOU to develop next-generation COVID-19 vaccine

To cooperate in clinical development of COVID-19 vaccine candidate GI-Cell aims to prioritize supplying to Korea and developing countries by developing a vaccine that accommodates mass supply, viral mutation response, safety, convenience of patients January 26, 2021, SEOUL, Korea – GI-Cell, an affiliate of GI-Innovation, […]

Cellid, IVI exchange ‘COVID-19 Vaccine Research Service Contract’

IVI to analyze samples from Phase 1/2a trials of Cellid’s COVID-19 vaccine to evaluate immunogenicity   January 5, 2021, SEOUL, Korea –  Cellid and the International Vaccine Institute (IVI) have exchanged a collaborative research agreement to analyze the immunogenicity of the COVID-19 vaccine “AdCLD-CoV19”.   […]

IVI-SK’s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal

Primary analysis also confirms safety of Vi-DT   December 17, 2020 – SEOUL, South Korea – Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary […]

EuBiologics partners up with IVI in COVID-19 vaccine development

December 3, 2020, SEOUL, South Korea – The International Vaccine Institute (IVI) and EuBiologics exchanged an MOU to cooperate in clinical development of the COVID-19 vaccine the company is currently developing. The signing ceremony at IVI headquarters on December 2 was attended by Dr. Jerome […]

How to take action on AMR during the COVID-19 pandemic, a webinar co-hosted by IVI, ICARS, and the Embassy of Denmark in Korea

Free webinar, Evidence to Action: Advancing the Antimicrobial Resistance Agenda during a Pandemic, will be held on Thursday, December 3, 2020 at 9:00 Central European Time (17:00 Korean Standard Time). Registration available at ivi.int/evidence-to-action/    December 1, 2020, SEOUL, Korea — The International Vaccine Institute […]

IVI celebrates GivingTuesday with local community heroes and launches new donation initiative

December 1, 2020, SEOUL, South Korea – The International Vaccine Institute (IVI) visited the Seoul Gwanak Police Station today to recognize the Foreign Affairs section for their ongoing support for IVI’s activities and to deliver protective face masks and medical supplies for staff and volunteers. […]

IVI, ROK’s GDEF join forces to provide OCV vaccination to 540,000 people at risk of cholera in Nepal and Mozambique

GDEF’s US$8.05 million grant to support ECHO projects to prevent and control cholera and contribute to ‘Ending Cholera—A Global Roadmap to 2030’   The International Vaccine Institute (IVI) and the Republic of Korea’s Global Disease Eradication Fund (GDEF) have agreed to conduct joint projects to […]

IVI and the Ministry of Foreign Affairs and Human Mobility of Ecuador exchange MOU to pursue global health research & development

November 24, 2020, SEOUL, Republic of Korea — The International Vaccine Institute (IVI) and the Ministry of Foreign Affairs and Human Mobility of Ecuador exchanged a memorandum of understanding (MOU) today at IVI headquarters in Seoul, Republic of Korea to explore areas of collaboration in […]

LG Electronics, IVI join forces to conduct a ‘cholera vaccination and prevention project’ in Ethiopia

Project to provide vaccination for 40,000 residents in areas at risk of cholera and establish disease monitoring system with the Ethiopian Ministry of Health through the Armauer Hansen Research Institute (AHRI) To contribute to health authorities in policymaking for disease prevention by investigating waterborne diseases […]

IVI, Vaccine Innovative Technology ALliance Korea (VITAL-Korea) to partner up for innovative vaccine research and development

Aim to accelerate R&D and globalization of Korean vaccines to increase contributions to global health     The International Vaccine Institute (IVI) and the Vaccine Innovative Technology ALliance Korea (VITAL-Korea) agreed to join forces to promote vaccine research and development for global health.   IVI […]

International Vaccine Institute honored with Minister of Health and Welfare Award for achievements in biosafety

October 28, 2020, SEOUL, Korea —  The International Vaccine Institute (IVI) received an award by the Minister of Health and Welfare of the Republic of Korea for achievements in biosafety management.   IVI was honored with the Minister of Health and Welfare Award for achievements in […]

The International Vaccine Institute Supports a Global Campaign to Reduce the Spread of Covid-19

The International Vaccine Institute (IVI) is partnering with the World Sanity Foundation (WSF) in a campaign to encourage the use of face masks in an effort to reduce the spread of COVID-19 cases until a safe and effective vaccine becomes widely available.   The first […]

IVI and global health partners encourage vaccine diplomacy

October 13, 2020, SEOUL, Korea — The International Vaccine Institute (IVI) hosted a virtual State Forum today to advocate for multilateral cooperation through vaccine diplomacy. During a coronavirus pandemic with the continuous threat of more neglected infectious diseases spreading around the world, the forum convened […]

Typhoid: Study confirms Vi-DT conjugate vaccine is safe and immunogenic in children 6-23 months of age

September 17, 2020 – SEOUL, South Korea – A new study conducted by IVI in collaboration with SK bioscience shows that single-dose and two-dose regimens of Vi-DT typhoid conjugate vaccine (TCV) are safe and immunogenic in children 6-23 months of age, a group with high […]

IVI to ready clinical trial sites for COVID-19 vaccine efficacy trials in 4 countries

September 9, 2020 – SEOUL, South Korea – The International Vaccine Institute (IVI) announced today that the Bill & Melinda Gates Foundation awarded close to 1.5 million USD to IVI to support clinical trial site preparedness in four African and Asian countries to potentially support future COVID-19 Phase III efficacy vaccine trials.     Following successful completion of early-stage clinical trials of COVID-19 vaccine candidates, it will be […]

IVI welcomes Finland as 36th member state with flag-raising ceremony

  August 10, 2020 – SEOUL, South Korea – The flag of Finland was raised at the International Vaccine Institute (IVI) Headquarters today during a ceremony welcoming the country’s accession to IVI. Finland joined the Seoul-based international organization dedicated to vaccines for global health in […]

IVI welcomes the First Lady of South Korea to a solidarity event for global health and vaccine equity

IVI hosted the “Shared Future, Global Solidarity: Vaccines Save Lives” event at its headquarters on July 8, 2020, attended by the First Lady, Minister of Health, Vice Minister of Foreign Affairs, Director of National Institute of Health of Korea, and foreign ambassadors to South Korea […]

LINE and International Vaccine Institute Release BT21 Donation Stickers to Promote Global Vaccination and Vaccine Development

LINE FRIENDS’ BT21 characters featured in IVI sticker set to raise funds for child immunization initiatives and COVID-19 vaccine development   SEONGNAM, South Korea – June 30, 2020 – LINE Corporation today released a set of animated stickers together with the International Vaccine Institute (IVI) […]

IVI welcomes H.E. Einar H. Jensen, Ambassador of Denmark to South Korea, to discuss COVID-19 and AMR research

  June 16, 2020, SEOUL, South Korea – The International Vaccine Institute (IVI) welcomed His Excellency Einar H. Jensen, Ambassador of Denmark to South Korea, to IVI’s headquarters today to discuss developments in COVID-19 research as well as the institute’s ongoing studies on antimicrobial resistance […]

IVI partners with Seoul National University Hospital to start Phase 1/2 clinical trial of INOVIO’s COVID-19 DNA (INO-4800) vaccine in South Korea

First COVID-19 vaccine clinical study approved in South Korea funded by CEPI through INOVIO, and supported by KCDC/KNIH 2-stage trial to test INOVIO’s COVID-19 vaccine (INO-4800) using well-established DNA platform technology in adults     June 4, 2020, SEOUL, Korea and PLYMOUTH MEETING, PA, USA […]

CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI

  June 3 2020, Oslo, Norway; Seoul, South Korea; Telangana, India—CEPI, the Coalition for Epidemic Preparedness Innovations, in collaboration with Ind-CEPI, has announced a new partnering agreement with a consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) to advance the development of […]

IVI standardizes on Veeva Vault QualityDocs to Improve Operational Efficiency

SEOUL, KOREA — March 10, 2020 — Veeva Systems (NYSE:VEEV) today announced that the International Vaccine Institute (IVI), a not-for-profit International Organization established in 1997 as an initiative by the United Nations Development Programme (UNDP), has implemented Veeva Vault QualityDocs to improve control and real […]

IVI presents COVID-19 vaccine and epidemiology research to H.E. Philippe Lefort, Ambassador of France to Korea

May 22, 2020, SEOUL, South Korea – The International Vaccine Institute (IVI) invited French Ambassador to Korea, Philippe Lefort, to IVI’s headquarters in Seoul, Korea today to share ongoing research and development on COVID-19.   His Excellency Philippe Lefort, French Ambassador to Korea (left), and […]

IVI to strengthen COVID-19 surveillance in sub-Saharan Africa with support from Sweden

IVI will leverage its network of infectious disease surveillance sites to conduct epidemiological studies of COVID-19 in Madagascar and Burkina Faso Sida’s contribution will significantly build in-country capacity to proactively respond to the pandemic     May 21, 2020 – SEOUL, South Korea – The […]

INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference

INO-4700 (GLS-5300) DNA vaccine demonstrates 100% binding and 92% neutralizing antibody responses against MERS-CoV INO-4800 DNA vaccine for COVID-19 currently in Phase 1 trial utilizes identical strategy targeting Spike protein and CELLECTRA intradermal delivery   PLYMOUTH MEETING, Pa. and SEOUL, KOREA – April 28, 2020 […]

LINE and International Vaccine Institute Team Up to Promote the Importance of Vaccination

LINE to offer an Official Account to IVI to promote the importance of vaccines and vaccination, as well as feature educational contents starring IVI Goodwill Ambassador Henry Lau LINE FRIENDS’ BT21 character IVI sticker set to be launched in the first half of the year […]

IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO’s COVID-19 DNA vaccine in South Korea

  The Coalition for Epidemic Preparedness Innovations (CEPI) grants funding $6.9 million to INOVIO and IVI to conduct clinical testing in Korea for INOVIO’s COVID-19 vaccine candidate based on their well-established DNA platform technology Korea National Institute of Health (KNIH) to support IVI’s testing efforts […]

International Vaccine Institute and Technical University of Denmark to strengthen external quality assurance in the face of rising antimicrobial resistance in Asia

The Asia Pacific region is vulnerable to the emergence and spread of AMR but there is little high-quality data available on the extent of its impact Quality-assured data is essential for building tailored strategies for preventing the spread of drug-resistant infections IVI is part of […]

IVI and Sweden renew partnership to accelerate vaccines for global public health

    January 13, 2020 – SEOUL, South Korea – The International Vaccine Institute (IVI), a Seoul, Korea-based international organization, announced today that the Swedish International Development Cooperation Agency (Sida) will continue to support IVI’s mission to accelerate vaccine research and development for global health […]

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

  January 9, 2020 – SEOUL, South Korea – The International Vaccine Institute (IVI) received a $1.4 million grant from the Bill & Melinda Gates Foundation to ensure critical standards and reagents are available to low-cost oral cholera vaccine (OCV) manufacturers in the global health […]

IVI appoints three new members to its Board of Trustees

December 18, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI), a Seoul, Korea-based international organization dedicated to accelerating vaccines for global health, announced today that Professor Gordon Dougan, Dr. Melanie Saville, and Dr. Jean-Marie Okwo-Bele will join its Board of Trustees (BOT) […]

IVI to Accelerate Efforts in iNTS Vaccine Development

An award from the Wellcome Trust’s Affordable Innovations for Global Health Flagship will support IVI’s development and selection of potential vaccine candidates There is currently no vaccine available to protect against invasive non-typhoidal salmonella (iNTS)   November 13, 2019 – SEOUL, South Korea – The […]

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

Institute expected to increase contributions to vaccine development activities worldwide   November 1, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI), an international organization for vaccine development and delivery headquartered in Seoul, has been granted Good Clinical Laboratory Practice (GCLP) certification by […]

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

October 28, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI) has received a $4.5 million grant from the Bill & Melinda Gates Foundation to simplify the current oral cholera vaccine (OCV) and further increase its accessibility. To date, the Gates Foundation has […]

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI State Forum 2019 was attended by 8th UN Secretary-General Ban Ki-moon, as well as 30 distinguished guests, including 17 ambassadors and top diplomats in Seoul, and senior Korean government officials.   The IVI State Forum 2019 was attended by ambassadors and senior diplomats from […]

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

September 24, 2019, SEOUL, Korea – The Chief Medical Officer for England, Dame Sally Davies, announced today during the 74th UN General Assembly that a consortium led by the International Vaccine Institute (IVI) has been awarded a £2.7m Fleming Fund Regional Grant to improve data […]

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

19th IVI International Vaccinology Course brings together 175 trainees and faculty members from 49 countries The annual course has trained over 1,544 healthcare professionals in vaccine development, evaluation, production and policy to help increase developing nations’ capacity in vaccine research and immunization.     September […]

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

  August 28, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI) has received additional funds of $4.33 million from the Bill & Melinda Gates Foundation to expand Severe Typhoid in Africa (SETA) Program activities in close alignment with the “Effect of a […]

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

August 16, 2019 – SEOUL, South Korea – Dr. Jerome Kim, Director General of the International Vaccine Institute (IVI), joins the Human Vaccines Project as one of four distinguished global leaders to help push forward its effort to solve one the greatest public health challenges […]

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

Fund to support IVI’s projects to vaccinate children in developing countries throughout Asia-Pacific and Africa, to develop vaccines against emerging viruses   Prof. Park Sang-chul, President of the Korea Support Committee for IVI, Prof. Sung Young-chul with his donation pledge and IVI Director General Dr. […]

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

Streptococcus pyogenes bacteria, which causes scarlet fever and other infections   30 May 2019, SEOUL, South Korea – The International Vaccine Institute (IVI) and Australia’s Murdoch Children’s Research Institute (MCRI) will coordinate a global push to free the world of Group A Streptococcus (Strep A), […]

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

SEOUL, South Korea — An international consortium, led by the International Vaccine Institute (IVI), has received funding from the UK’s Fleming Fund Regional Grants to conduct the Capturing Data on Antimicrobial Resistance (AMR) Patterns and Trends in Use in Regions of Asia (CAPTURA) project. The […]

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

– Grant from the Bill & Melinda Gates Foundation will support additional supply of novel TCV at affordable cost for public sector markets   SEOUL, Korea –The International Vaccine Institute (IVI) announces receipt of a $15.7 million-dollar grant from the Bill & Melinda Gates Foundation […]

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

– Event organized by IVI to discuss ways of cooperation to help increase Korea’s vaccine self-sufficiency, and accelerate globalization of the Korean vaccine industry Key participants pose for a commemorative photo at the ‘IVI Forum for Enhancement of Cooperation’ at the National Assembly of the […]

Vaccine study confirms sensitivity of cholera test

Recently, the sensitivity of fecal microbiological cultures for detecting cholera has come under question. Researchers reporting in PLOS Neglected Tropical Diseases investigated this claim using a ‘vaccine probe’ analysis of a completed cholera vaccine cluster randomized trial to support the sensitivity of conventional microbiological culture […]

Korean Pediatric Association, IVI, KSC exchange MOU

KPA, as group of experts in pediatric infectious diseases, to collaborate in academic research and projects on infectious disease prevention To support vaccination of children in developing countries through the ‘One for Three’ campaign, in partnership with IVI     The International Vaccine Institute (IVI), […]

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

  SEOUL, Korea — The International Vaccine Institute (IVI) has been awarded a $3,238,974 grant from the Bill & Melinda Gates Foundation to provide technical assistance support for studies to measure the effectiveness of typhoid conjugate vaccine (TCV) in West Africa. This grant comes after […]

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

– Bilateral ‘Master Implementing Partner Services Agreement’ expected to enable IVI to provide technical capabilities to CEPI   Oslo, Norway; Seoul, Republic of Korea 11 February 2019—The Coalition for Epidemic Preparedness Innovations (CEPI) and the Republic of Korea-based International Vaccine Institute (IVI), an international organisation […]

Henry Lau joins IVI as Goodwill Ambassador

– Singer-songwriter, Henry to team up with the International Vaccine Institute (IVI), founded by the United Nations Development Programme to develop and deliver new vaccines for global health – IVI Director General Dr. Jerome Kim: “IVI is privileged to have Henry on board, and grateful […]

Nature Communications study addresses MDR typhoid

New study in Nature Communications reveals high burden of multi-drug resistant (MDR) typhoid fever in sub-Saharan Africa associated with two predominant genotypes – IVI epidemiologist Se Eun Park and collaborating scientists report data from Typhoid Fever Surveillance in Africa (TSAP) program and other sources   […]

THSTI, IVI held joint symposium on Nov. 22

First cooperative program between International Vaccine Institute and Translational Health Science and Technology Institute expected to help accelerate cooperation between India and IVI IVI and the Translational Health Science and Technology Institute (THSTI) of India held a joint symposium at IVI headquarters on November 22. […]

‘The Euvichol story’ published in Vaccine

“The Euvichol Story – Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships” spearheaded by the International Vaccine Institute (IVI), has been published in Vaccine by Elsevier. The Euvichol Story published on October 9, 2018 in the […]

IVI accelerates development of MERS vaccine

– Institute jointly conducts phase 1/2a clinical trial of GeneOne Life Science’s GLS-5300 DNA MERS vaccine – IVI in search of additional promising candidate vaccines among developers worldwide, with support from Samsung Life Public Welfare Foundation   The International Vaccine Institute (IVI) said on September […]

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

Annual Course to update on the recent development in vaccinology, including basics of immunology, epidemiology, vaccine design and development Featured experts include: Stanley Plotkin (University of Pennsylvania), Dr. Barney Graham (US NIH), Dr. Randy Schoepp (USAMRID), Dr. Andy Pollard (University of Oxford), and Dr. Eric […]

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

– Joint initiative aims to prevent and control cholera, and secure sustainable cholera and diarrheal disease surveillance  – WASH campaign to promote access to clean water and behavioral change for appropriate sanitation and hygiene practice – “KOICA is joining the program to contribute to ‘Ending […]

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience

– Grant from the Bill & Melinda Gates Foundation to allow SK Bioscience Co. Ltd, IVI to accelerate late-stage development of new vaccine necessary to achieve WHO prequalification The International Vaccine Institute (IVI), an international nonprofit organization devoted to providing vaccines critical to global public […]

×

Christian Loucq inaugurated as Director-General of IVI

Author
Master
Date
2012-05-31 00:00
Views
5296
 
NEWS RELEASE
International Vaccine Institute
 
FOR IMMEDIATE RELEASE
2011-12-19  (KST)
 
Christian Loucq inaugurated as Director-General of IVI
 

-New vision emphasizes translating outcomes of vaccine research to saving lives of the world´s poor

 

SEOUL, KOREA- Dr. Christian Loucq was inaugurated as the new head of the International Vaccine Institute (IVI), an international organization devoted to research in vaccine development and introduction for the developing world, on December 19th. Dr. Loucq will serve an initial four-year term to build upon the Institute’s successes achieved under the leadership of his predecessor Dr. John Clemens.

IVI´s new Director-General, Dr. Christian Loucq, presents his vision for IVI during a press briefing following the inaugural ceremony.

More than 120 people attended the ceremony held at the IVI headquarters in Seoul. Participants included Prof. Ragnar Norrby, Chairman of the IVI Board of Trustees; Mr. Kim Bong-hyun, Deputy Minister for Multilateral and Global Affairs at the Korean Ministry of Foreign Affairs and Trade (MOFAT); Dr. Suh You-mi, Director-General for International Cooperation at the Ministry of Education, Science and Technology (MEST); Ms. Paik Ji-ah, Director-General for the International Organizations Bureau at the MOFAT; Dr. Lance Gordon, Deputy Director, Infectious Diseases, Global Health & SPL for Neglected Infectious Diseases from the Bill and Melinda Gates Foundation; Prof. Cho Dong-sung, President of the Korea Support Committee for IVI; and ambassadors and members of the diplomatic corps based in Seoul that represent IVI’s signatory countries.

 

“I am humbled, honored, and very enthusiastic to be joining the IVI team as Director-General. Since its establishment in 1997, IVI has been a pioneering organization in many aspects of vaccinology - from R&D to epidemiology and from local manufacturing to access - aimed at preventing infectious diseases among the world´s poorest children,” Dr. Loucq said. “As the new Director-General, I will strive to increase IVI’s impact in the fight against infectious diseases in developing countries, based on its scientific contributions to the research, development and optimal use of new and improved vaccines."

Prof. Ragnar Norrby, Chairman of the IVI Board presents Dr. Loucq his certificate of appointment as Director-General.

Dr. Loucq has devoted his entire career to vaccines. Originally from France, he has professional experience in medicine, vaccines, pharmaceuticals, and global health in countries that include Algeria, Belgium, Chad, China, India, the Netherlands, Niger, Switzerland, Thailand, the U.S., and the U.K. In addition, he managed vaccine businesses in China, India and Thailand, and worked with major vaccine companies such as GlaxoSmithKline (GSK) and Sanofi Pasteur.

 

Most recently, Dr. Loucq was the Director of the Malaria Vaccine Initiative (MVI), a product development partnership based at PATH in the U.S. MVI in collaboration with GSK and 11 teams of African scientists successfully spearheaded a major clinical trial of an experimental malaria vaccine at 11 sites in seven countries in Africa. Initial findings suggest the vaccine can effectively halve the risk of malaria infection, and it may become the world´s first viable vaccine against this deadly disease.

 

“IVI is most fortunate to have someone of Dr. Loucq’s caliber as its leader,’” said Prof. Norrby. “His distinguished track record and background in global public health and business makes him an ideal leader to effectively set the course for IVI’s continued success as an institute.”

 

The appointment of Dr. Loucq as IVI’s Director-General is especially timely, considering the momentum in the global health community to increase the use of live-saving vaccines for the developing world. The Decade of Vaccines, a 10-year commitment spearheaded by Bill and Melinda Gates to accelerate the discovery, development, and delivery of vaccines to the world’s poorest countries, has been a key catalyst in getting governments, the private sector, and the public sector more involved.

 

Notably, Korea has become a country of interest for global health, as indicated by recent high-profile meetings between Mr. Bill Gates and President Lee Myung-bak and its entry into the Organization for Economic Co-operation and Development’s Development Assistance Committee (DAC), a high-level forum consisting of the world’s major donor countries. Korea’s entry into DAC was significant since it was the first member to transition from a recipient of foreign aid to a donor. These developments have ignited national interest in Korea’s role in international development and cooperation efforts, including the development and deployment of vaccines for poor countries, work that is spearheaded by IVI.

 

As the host country of IVI, the government of Korea has provided generous support to ensure that the Institute seamlessly carries out its global mission through the donation of the Institute’s headquarters building with state-of-the-art laboratories, and contributing to IVI’s annual operating budget. When it made the successful bid to host IVI in the 1990s, Korea wished to repay what it received from the international community during and after the Korean War, and has been one of IVI’s most generous donors to date.

 

With support from Korea and donors such as the government of Sweden and the Bill & Melinda Gates Foundation, IVI conducts research in more than 30 countries of Asia, Africa and Latin America, including North Korea. Through IVI, the world’s first low-cost oral cholera vaccine, Shanchol™, was developed. The vaccine recently achieved World Health Organization prequalification and is ready for global use, with plans to deploy the vaccine in Haiti, India, Bangladesh, and Ethiopia to combat cholera. As well, the Institute is developing new and improved vaccines against typhoid fever and dysentery, two deadly diarrheal diseases in the developing world.

 

“Korea’s support of IVI best exemplifies the country’s desire to contribute to the world,” Dr. Loucq said. “I look forward to strengthening our partnership with the Korean government and building new partnerships around the world in which together, we will make major contributions to achieving our shared vision of a world where all children living in the world´s poorest countries are protected by vaccines against killer infectious diseases.”



About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established as an initiative of the United Nations Development Program in 1997, IVI operates as an independent international organization under a treaty signed by 40 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa, and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Korea. For more information, please visit: www.ivi.int

 

Attachment 1: Inaugural address, Dr. Christian Loucq, IVI Director-General

Attachment 2: Speeches for inauguration of IVI Director-General Dr. Christian Loucq

 
IVI CONTACT : Tae Kyung Byun (Public Awareness / Advocacy Officer)
82-2-881-1159 Cellular: 011-9773-6071
IVI, SNU Research Park, San 4-8, Bongcheon 7-dong, Gwanak-gu, Seoul, South Korea, 151-818
Phone: 82-2-872-2801, Cellular: 011-9773-6071, Fax: 82-2-872-2803 www.ivi.int e-mail: tkbyun@ivi.int
 
DONATE